|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2010-11-22
|
|
pubmed:abstractText |
Pyridostigmine is the first drug of choice for patients with myasthenia gravis (MG). The drug is not prescribed regularly to any other patient groups. We aimed to determine the prevalence, incidence and gender-specific characteristics of patients with MG needing drug treatment in a well-defined population cohort.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1468-1331
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
© 2010 The Author(s). European Journal of Neurology © 2010 EFNS.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1445-50
|
|
pubmed:meshHeading |
pubmed-meshheading:20491896-Age Distribution,
pubmed-meshheading:20491896-Cohort Studies,
pubmed-meshheading:20491896-Drug Utilization,
pubmed-meshheading:20491896-Female,
pubmed-meshheading:20491896-Humans,
pubmed-meshheading:20491896-Incidence,
pubmed-meshheading:20491896-Male,
pubmed-meshheading:20491896-Myasthenia Gravis,
pubmed-meshheading:20491896-Norway,
pubmed-meshheading:20491896-Prevalence,
pubmed-meshheading:20491896-Pyridostigmine Bromide,
pubmed-meshheading:20491896-Sex Distribution
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Myasthenia gravis requiring pyridostigmine treatment in a national population cohort.
|
|
pubmed:affiliation |
Department of Clinical Medicine, Section for Neurology, University of Bergen, Bergen, Norway. jintanaandersen@gmail.com
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
